Introduction
The CBC documentary Cracking Cancer and the related patient story about precision oncology are useful because they show both the promise and the limits of genomic medicine. The central idea is straightforward: instead of treating cancer only according to the organ in which it began, researchers analyze the molecular features of an individual tumor and look for biological changes that may suggest a targeted treatment. British Columbia’s Personalized OncoGenomics (POG) program was created for patients with advanced cancers and combines genomic and clinical information to understand why some tumors respond to particular therapies while others do not (BC Cancer, 2026). The documentary makes this research understandable through patient stories, but a critical analysis must distinguish an exceptional response from evidence that precision oncology benefits every patient. Genomic sequencing can reveal actionable alterations, clarify tumor biology, and occasionally identify unexpected treatment options, yet many patients do not have a target linked to an effective drug. Contemporary precision oncology has advanced substantially since the documentary was produced, but its basic lesson remains accurate: molecular information can change treatment decisions, while uncertainty, resistance, access, and clinical evidence remain central.
POG Program
The documentary follows people with advanced cancers enrolled in the POG program, where researchers compare molecular information from the tumor with normal tissue and combine that information with clinical history. This tumor-normal comparison helps identify genetic alterations that are acquired by the cancer rather than inherited throughout the patient’s body. The goal is not simply to produce a long list of mutations. Researchers must decide which findings are biologically important, whether a drug exists that affects the relevant pathway, whether there is evidence that the drug works in the patient’s cancer context, and whether treatment is clinically available. That process is what makes a finding “actionable.” BC Cancer continues to describe POG as a research program in which doctors and scientists study genomic and clinical information from advanced cancers to support more personalized approaches to care (BC Cancer, 2026).
One of the documentary’s strengths is that it shows precision medicine as a collaborative interpretation problem rather than a machine that automatically chooses treatment. Sequencing produces data, but oncologists, pathologists, geneticists, bioinformaticians, and researchers must interpret that data in relation to the tumor’s behavior and the patient’s condition. Modern oncology has moved even further in this direction. A 2023 review of precision oncology noted that treatment selection increasingly depends not only on a single mutation but on combinations of genomic changes, immune biomarkers, signaling pathways, and the biological context in which an alteration occurs (Murciano-Goroff et al., 2023). The documentary therefore anticipated a field that has become more sophisticated, but it also correctly shows why precision oncology requires multidisciplinary expertise.
Exceptional Responses
The patient stories in Cracking Cancer are emotionally powerful because some individuals experience responses after standard treatment options have become limited. In the case of Zuri Scrivens, molecular analysis suggested that a drug developed for another purpose might affect a pathway active in her cancer. Drug repurposing is scientifically plausible because a medicine’s biological effect can sometimes matter more than the disease for which it was originally marketed. However, a responsible summary should not say that such a treatment “cured” advanced cancer unless the clinical evidence supports that conclusion. Oncology uses specific terms such as complete response, partial response, stable disease, remission, progression-free survival, and overall survival. These outcomes can be highly meaningful without proving that every cancer cell has been permanently eliminated.
This distinction is important because advanced tumors are genetically diverse and can evolve under treatment pressure. A therapy may eliminate sensitive cancer cells while resistant populations survive and later expand. Precision medicine therefore does not remove the problem of resistance; in some cases it reveals it more clearly. NCI describes targeted therapy as treatment directed at proteins that control cancer-cell growth, division, or spread, but also notes that cancers can become resistant when targets change or alternative pathways allow continued growth (NCI, 2022). The documentary’s best moments preserve the tension between hope and uncertainty. Patients may gain additional time, symptom relief, or a strong response, but precision oncology is not equivalent to a guaranteed cure.
Precision Oncology Advances
Since the original POG stories, genomic testing has become more common and more targeted therapies have been approved for biomarker-defined cancers. Some treatments are now “tissue agnostic,” meaning eligibility depends primarily on a molecular feature rather than the organ where the cancer started. NCI lists several gene- and immune-targeted therapies approved for patients with specific biomarkers across different solid tumors, reflecting a major shift in oncology (NCI, 2025a). The NCI-MATCH trial also helped establish the feasibility of assigning treatment according to tumor genetics, and its successors—including ComboMATCH—are testing combinations of targeted treatments for tumors with defined molecular changes (NCI, 2026a). These developments support the documentary’s central claim that cancer can sometimes be understood more effectively through its molecular drivers than through anatomy alone.
At the same time, the modern evidence base also clarifies the limitations. A comprehensive 2023 review of next-generation sequencing in advanced cancer found that broad genomic profiling can affect treatment selection and outcomes for some patients, but the size of the benefit depends on cancer type, available drugs, timing, and whether identified alterations have strong clinical evidence behind them (Gibbs et al., 2023). Many mutations remain difficult to target. Some suggested treatments are unavailable, too toxic, or supported only by early evidence. Others may look promising biologically but fail in clinical trials. Precision oncology is therefore a method for improving the probability of selecting an effective therapy, not a replacement for randomized evidence, pathology, or clinical judgment.
Super Responders
The companion article about a cancer survivor is valuable because it turns an abstract research program into a human story. It describes a patient with recurrent ovarian cancer whose molecular characteristics helped guide treatment and who experienced an unusually strong response. The term “super responder” is often used informally for a patient whose response is deeper or longer than expected. Such cases can be scientifically valuable because researchers may study them to understand why a treatment worked unusually well. They can generate hypotheses about biomarkers, pathways, immune response, or drug sensitivity that may later be tested in larger groups. However, one extraordinary response cannot establish the average effectiveness of a treatment.
The ovarian-cancer context also illustrates how precision medicine can interact with established biomarker-based treatment. PARP inhibitors, for example, became important in ovarian cancer partly because tumors with deficiencies in homologous recombination repair—particularly those involving BRCA1 or BRCA2—may be especially sensitive to this class of drugs. The broader principle is that genomic information can identify biological vulnerabilities. Modern precision oncology now extends beyond DNA sequencing alone. Researchers increasingly combine DNA, RNA, protein, immune, and sometimes functional drug-response data. NCI highlighted in 2024 how single-cell gene-expression information may help predict responses to cancer drugs, while proteogenomic research has identified potential treatment targets not evident from DNA analysis alone (NCI, 2024a; 2024b). The field is therefore moving from simple mutation matching toward multi-layered tumor characterization.
Strengths and Limitations
Both the documentary and article succeed as public communication because they make complex genomic science understandable without beginning from abstract laboratory techniques. Patients give the research emotional meaning and demonstrate why experimental options matter when standard therapy has failed. The accounts also show the importance of collaboration among researchers and clinicians. Their major limitation is the risk inherent in storytelling itself: exceptional cases are more compelling than ordinary ones. A patient whose tumor has no actionable alteration, who cannot access a matched drug, or who does not respond is less likely to become the center of a public narrative. Readers can therefore overestimate the probability of benefit if they do not distinguish individual cases from population-level evidence.
A second limitation is that precision oncology raises questions about equity and access. Genomic testing, specialized interpretation, clinical trials, and targeted drugs may not be equally available to all patients. Research has identified ancestry-related disparities in access to precision-oncology assays, showing that technological progress can coexist with unequal use (Ding et al., 2023). Cost, geography, insurance, trial eligibility, tissue availability, and representation in genomic databases can all influence who benefits. Precision medicine is most ethically valuable when innovation is paired with systems that expand access rather than concentrating advanced diagnostics among patients who already have greater healthcare resources.
Future of Cancer Care
The enduring value of Cracking Cancer is not that it predicted a future in which every tumor would have one mutation and one perfect drug. The field has instead moved toward increasingly complex models in which genomic information is one component of treatment selection. Current research includes targeted therapy, immunotherapy biomarkers, combination treatments, tissue-agnostic approvals, whole-genome sequencing, proteogenomics, single-cell analysis, and functional testing of living tumor material. NCI now describes functional precision medicine as an important research opportunity because most patients still do not have a genetic alteration that directly indicates a specific targeted therapy (NCI, 2026b). This is a significant correction to early optimism: sequencing has transformed oncology, but it has not solved cancer.
The future is likely to involve combining molecular information with conventional oncology rather than replacing it. Tumor location, stage, pathology, previous treatment, patient health, treatment goals, and personal preferences remain essential. Genomic findings are most useful when they change a decision that can actually be acted upon. This makes evidence quality crucial. A laboratory finding, a theoretical pathway, and a treatment proven to improve survival are not equivalent levels of evidence. Patients need communication that preserves hope without overstating certainty.
Conclusion
Cracking Cancer and the associated precision-oncology patient narrative remain valuable because they show how genomic analysis can reveal treatment possibilities that traditional classifications may miss. Their strongest contribution is not proof that personalized genomics cures advanced cancer, but a demonstration of how tumor biology can guide more individualized decisions. Modern evidence confirms that precision oncology has expanded, with more biomarker-directed drugs, tissue-agnostic approvals, and clinical trials based on molecular features. It also confirms the limitations visible in the original stories: not every tumor has an actionable target, a molecular match does not guarantee response, resistance can emerge, and access is unequal. Exceptional responders are scientifically important, but they should not be presented as typical outcomes. The most accurate interpretation is therefore balanced. Genomic medicine has changed cancer care and will continue to do so, but its value depends on rigorous evidence, multidisciplinary interpretation, realistic communication, and equitable access to the testing and treatments that precision oncology makes possible.
References
BC Cancer. (2026). Personalized OncoGenomics (POG).
Ding, L., et al. (2023). Disparities according to genetic ancestry in the use of precision oncology assays. New England Journal of Medicine, 388, 281–283. https://doi.org/10.1056/NEJMc2213457
Gibbs, S. N., Peneva, D., Carter, G. C., & Palomares, M. R. (2023). Comprehensive review on the clinical impact of next-generation sequencing tests for the management of advanced cancer. JCO Precision Oncology, 7, e2200715. https://doi.org/10.1200/PO.22.00715
Murciano-Goroff, Y. R., Suehnholz, S. P., Drilon, A., & Chakravarty, D. (2023). Precision oncology: 2023 in review. Cancer Discovery, 13(12), 2525–2531. https://doi.org/10.1158/2159-8290.CD-23-1194
National Cancer Institute. (2022). Targeted therapy to treat cancer.
National Cancer Institute. (2024a). NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients.
National Cancer Institute. (2024b). Study identifies hundreds of potential targets for cancer drugs.
National Cancer Institute. (2025a). Agnostic cancer therapies (PDQ).
National Cancer Institute. (2026a). ComboMATCH precision medicine cancer trials.
National Cancer Institute. (2026b). Highlighted scientific opportunities in cancer research: Advancing functional precision medicine.
Academic Master Education Team is a group of academic editors and subject specialists responsible for producing structured, research-backed essays across multiple disciplines. Each article is developed following Academic Master’s Editorial Policy and supported by credible academic references. The team ensures clarity, citation accuracy, and adherence to ethical academic writing standards
Content reviewed under Academic Master Editorial Policy.
